- Market Capitalization, $K 542,096
- Shares Outstanding, K 46,472
- Annual Sales, $ 173,320 K
- Annual Income, $ -132,990 K
- 60-Month Beta 1.00
- Price/Sales 3.23
- Price/Cash Flow N/A
- Price/Book N/A
|Period||Period Low||Period High||Performance|
| || |
-0.28 (-2.37%)since 08/21/20
| || |
-2.66 (-18.50%)since 06/22/20
| || |
-16.75 (-58.83%)since 09/20/19
Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Radius (RDUS) completes enrollment in its phase III study assessing a wearable abaloparatide-transdermal patch in the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced data presentations on abaloparatide-SC at the upcoming American Society for Bone and Mineral Research (ASBMR) 2020 Annual...
-- Innovative transdermal technology enables delivery of abaloparatide molecule - a peptide - across the skin
Radius Health, Inc. (Nasdaq: RDUS) today announced its participation in the following conferences in September 2020.
Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced a business update including the extension of the patent for TYMLOS as well as the completion of enrollment for its Phase 3...
Radius (RDUS) reports a wider-than-expected loss but beats sales estimates in the second quarter.
Radius Health (RDUS) delivered earnings and revenue surprises of -15.85% and 3.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
WALTHAM, Mass. (AP) _ Radius Health Inc. (RDUS) on Monday reported a loss of $43.9 million in its second quarter.
Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with immediate effect.